Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Should you microdose your GLP-1
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
GPhC 2228233 Fahima Tamannah Prescribing Pharmacist A personable approach to help drive patients towards their weight-loss goals and long-term health
It provides critical data on liver health, detoxification, and metabolic disorders
Both increase growth hormone naturally but through distinct biological mechanisms
